USWM CT

US WorldMeds (USWM) is a specialty pharmaceutical company headquartered in Louisville, Kentucky, focused on developing and commercializing therapies for rare and challenging conditions. In July 2025, the company significantly expanded its oncology presence by acquiring the cell therapy portfolio of Adaptimmune through its subsidiary USWM CT, LLC. This landmark acquisition included Tecelra, the first FDA-approved engineered cell therapy for a solid tumor (synovial sarcoma), along with late-stage candidates lete-cel and uza-cel. USWM's existing portfolio features Iwilfin for high-risk neuroblastoma, Revonto for malignant hyperthermia, and Sevenfact for hemophilia. The company operates with a focus on niche markets and unmet medical needs in hematology, oncology, and rare diseases.